Gimoti Shortage: What Providers and Prescribers Need to Know in 2026

Clinicians managing patients with diabetic gastroparesis should be aware that Gimoti (metoclopramide nasal spray) is not subject to an FDA manufacturing shortage as of 2026 — but that doesn't mean your patients will have an easy time accessing it. Gimoti's specialty-only distribution model creates access barriers that can delay treatment by weeks. This guide summarizes the key clinical and logistical facts you need to know to prescribe Gimoti effectively in 2026.

Current Access Status: What the FDA Data Shows

As of 2026, Gimoti is not listed on the FDA Drug Shortage Database. Supply from Evoke Pharma, Inc. and manufacturer Patheon (a Thermo Fisher division) has been maintained. However, access is functionally limited by the exclusive specialty pharmacy distribution model: all Gimoti prescriptions must be routed to ASPN Pharmacies. Patients who receive their prescription at a retail pharmacy will not be able to fill it.

The ASPN Pharmacies Model: What Prescribers Must Know

Gimoti is only available through ASPN Pharmacies. This is not optional — if your prescription is sent to any other pharmacy, the patient will not receive their medication. Key routing information:

ASPN Pharmacies phone: 1-844-244-6684 (1-844-2GIMOTI)

Fax: 1-888-661-9657

NCPDP#: 3147863 | NPI: 1538590690 | ZIP: 07039

ASPN also manages PA initiation via electronic PA (ePA) or fax, and handles appeals.

Payer Coverage and Prior Authorization Criteria

Most commercial insurers require PA for Gimoti. Common criteria include:

Patient is 18 years of age or older.

Confirmed diagnosis of acute and recurrent diabetic gastroparesis (not general nausea/vomiting).

Documentation of inadequate response or intolerance to oral metoclopramide (samples/coupons excluded from consideration).

Prescriber attestation to benefits vs. risks of metoclopramide, including tardive dyskinesia risk.

When completing PA documentation, note specifically: (1) documented gastroparesis diagnosis with gastric emptying study confirmation, (2) duration and doses of prior oral metoclopramide trials, and (3) reason for transition to nasal route (e.g., swallowing difficulty, severe nausea limiting oral drug retention, inadequate relief from oral form).

Clinical Considerations: When Gimoti Is Preferred Over Oral Metoclopramide

Gimoti's nasal route provides a clinical advantage in specific patient populations where oral drug absorption is compromised or oral administration is difficult:

Patients with severe gastroparesis who experience frequent vomiting or are unable to retain oral medications.

Patients who had variable therapeutic response with oral metoclopramide, potentially attributable to erratic gastric absorption.

Patients with dysphagia or difficulty swallowing tablets.

Gimoti 15 mg nasal spray was shown to be bioequivalent to oral metoclopramide 10 mg tablet in pharmacokinetic studies. The nasal route bypasses the delayed gastric emptying that can impair oral drug absorption in these patients.

Key Contraindications and Special Populations to Screen

History of tardive dyskinesia or dystonic reaction to metoclopramide — absolute contraindication.

Parkinson's disease — contraindicated; metoclopramide exacerbates parkinsonian symptoms.

Renal impairment (CrCl < 60 mL/min) / Hepatic impairment (Child-Pugh B or C) — not recommended; dose cannot be adjusted for the nasal spray formulation.

CYP2D6 poor metabolizers and patients on strong CYP2D6 inhibitors — not recommended; increased metoclopramide exposure cannot be dose-adjusted with the spray.

Geriatric patients — not recommended as initial therapy. May only be used if already on stable oral metoclopramide 10 mg QID, with a switch to Gimoti 15 mg nasal spray QID.

Epilepsy — contraindicated; metoclopramide may increase seizure frequency.

The 12-Week Maximum Duration Rule

The FDA boxed warning for Gimoti requires avoiding treatment with any metoclopramide product (including all oral, injectable, and nasal formulations) for longer than 12 weeks due to the risk of tardive dyskinesia. This cumulative 12-week limit applies across all metoclopramide dosage forms. In your documentation, track the total duration and cumulative dose of metoclopramide exposure across all forms.

If longer-term use is clinically unavoidable, the 2026 FDA-approved label states that providers should routinely monitor for signs and symptoms of TD. Discuss the risks explicitly with patients and document informed consent.

Clinical Alternatives When Gimoti Is Not Appropriate

Erythromycin (off-label): AGA-recommended as a conditionally supported option. Use low doses (40–150 mg before meals via oral suspension) to minimize side effects. Note tachyphylaxis risk after ~4 weeks.

Domperidone (expanded access): Requires FDA IND application. Monitor ECG for QTc prolongation. Avoid if QTc >470 ms (males) or >450 ms (females).

Antiemetics: Ondansetron 4–8 mg TID PRN for nausea; does not accelerate gastric emptying but provides symptomatic relief.

How medfinder Can Support Your Patients' Access

For patients managing multiple medications alongside Gimoti, access delays at any one pharmacy can disrupt their entire treatment regimen. medfinder for providers helps your patients quickly identify which pharmacies near them have their medications in stock, reducing the phone-calling burden and keeping patients on their prescribed therapies.

See also: How to Help Your Patients Find Gimoti In Stock: A Provider's Guide.